Request a Quote |

Cyprotex enters significant long-term contract with Sepracor

Cyprotex PLC (LSE:CRX), the drug discovery technology and information company, is pleased to announce that it has entered into a significant long-term contract for Cyprotex's integrated Cloe offering with the major US-based pharmaceutical company, Sepracor Inc.

Commenting on the agreement, Robert Morrisson Atwater, Chief Executive Officer of Cyprotex PLC, said: "This is Cyprotex's first major US partnership which shows that our technologies, expertise and general approach are attracting a wider audience. This deal is clear demonstration that Cyprotex is gaining well deserved recognition as a valuable partner in drug discovery."

For further information:

Cyprotex PLC
Robert Morrisson Atwater, Chief Executive Officer
Tel: +44 (0) 1625 505 100
ir@cyprotex.com
www.cyprotex.com

Media Enquires:

Abchurch Communications
Heather Salmond / Samantha Robbins
Tel: +44 (0) 20 7398 7700
samantha.robbins@abchurch-group.com
www.abchurch-group.com

Contact us

News categories

Archives

Contact us to discuss your ADME Tox issues or request a quote

Telephone:
North America (East Coast): +1-888-297-7683
Europe: +44 (0)1625 5051000

 

or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.

By clicking on ‘Send’ I agree that my data is being transferred and used by Cyprotex and the affiliated Evotec Group. The Evotec Group currently consists of the following companies. For further details please see our privacy policy.

If you would like to be kept informed of our latest services, new research, events and other news please tick the box below:

Close